- Report
- April 2025
- 44 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- April 2025
- 94 Pages
Global
From €5308EUR$5,600USD£4,434GBP
- Report
- October 2024
- 318 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Report
- January 2025
- 250 Pages
Global
From €4738EUR$4,999USD£3,958GBP
- Report
- May 2018
- 204 Pages
Global
From €2226EUR$2,349USD£1,860GBP
- Report
- April 2024
- 115 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- March 2024
- 30 Pages
Global
From €2606EUR$2,750USD£2,178GBP
- Drug Pipelines
- April 2024
- 230 Pages
Global
From €2843EUR$3,000USD£2,376GBP
- Book
- July 2023
- 1568 Pages
- Book
- October 2024
Global
Apomorphine is a drug used to treat Parkinson's disease and other central nervous system disorders. It is a dopamine agonist, meaning it stimulates dopamine receptors in the brain, which helps to reduce the symptoms of Parkinson's disease. Apomorphine is administered as an injection or infusion, and is available in both oral and sublingual forms. It is also used to treat drug-induced Parkinsonism, a condition caused by certain medications.
Apomorphine is a relatively new drug, and its use is still being studied. It is generally considered to be a safe and effective treatment for Parkinson's disease, although it can cause side effects such as nausea, vomiting, and dizziness.
The apomorphine market is growing, as more people are being diagnosed with Parkinson's disease and other central nervous system disorders. The market is expected to continue to grow as new treatments are developed and more people are diagnosed with these conditions.
Some companies in the apomorphine market include Merck, Novartis, and Teva Pharmaceuticals. Show Less Read more